All In Biotech

Drug Trial Radar · NCT04680949

suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19

suPAR-Guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial

Last checked: Nov 20, 2026Latest source record: Sep 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 606 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

606

Actual

Start

Dec 23, 2020

Primary completion

Mar 31, 2021

Study completion Feb 6, 2022

Sponsor

Lead sponsor
Hellenic Institute for the Study of SepsisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The SAVE-MORE is a pivotal, confirmatory, phase III randomized clinical trial (RCT) aiming to evaluate the efficacy and safety of early start of anakinra guided by suPAR in patients with LRTI by SARS-CoV-2 in improving the clinical state of COVID-19 over 28 days as measured by the ordinal scale of the 11-point World Health Organization (WHO) clinical progression scale (CPS).

Conditions

  • Covid19

Interventions

  • AnakinraDrug

    Standard-of-care and anakinra. Anakinra is injected subcutaneously as 100 mg once daily for 10 days

  • PlaceboDrug

    Standard-of-care and placebo. Placebo is injected subcutaneously once daily for 10 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of the distribution of frequencies of each score of a 5-scale patient state evaluated from the 11-point WHO Clinical Progression ordinal Scale (CPS) between the two arms of treatmentTime frame: 28 days

Locations

40 sites in 2 countries. Site status is shown where the registry gives one.

  • 2nd Department of Internal Medicine, University General Hospital of Alexandroupolis

    Alexandroupoli, Greece

  • 10th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens

    Athens, Greece

  • 1st Department of Internal Medicine, AMALIA FLEMING Prefecture General Hospital of Melissia

    Athens, Greece

  • 1st Department of Internal Medicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S.

    Athens, Greece

  • 1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO

    Athens, Greece

  • 1st Department of Internal Medicine, General Hospital of Nea Ionia CONSTANTOPOULIO-PATISION

    Athens, Greece

  • 1st Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO

    Athens, Greece

  • 1st University Department of Internal Medicine, General Hospital of Athens LAIKO

    Athens, Greece

  • 1st University Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens

    Athens, Greece

  • 2nd Department of Internal Medicine, General Hospital of Eleusis THRIASIO

    Athens, Greece

  • 2nd Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens

    Athens, Greece

  • 2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens

    Athens, Greece

  • 3rd Department of Internal Medicine, General Hospital of Athens KORGIALENEIO-BENAKEIO E.E.S.

    Athens, Greece

  • 3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens SOTIRIA

    Athens, Greece

  • 4th Department of Internal Medicine, ATTIKON University General Hospital

    Athens, Greece

  • 4th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens

    Athens, Greece

  • 5th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens

    Athens, Greece

  • COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING

    Athens, Greece

  • Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens

    Athens, Greece

  • Department of COVID-19, Evangelismos General Hospital

    Athens, Greece

  • Department of Internal Medicine, General Hospital of Athens Elpis

    Athens, Greece

  • • 1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS

    Athens, Greece

  • • Department of Internal Medicine, General Hospital of Chest Diseases of Athens SOTIRIA

    Athens, Greece

  • Department of Pulmonary Medicine, General Hospital of Kerkyra

    Corfu, Greece

  • 1st Department of Internal Medicine, General University Hospital of Ioannina

    Ioannina, Greece

  • Department of Internal Medicine, University General Hospital of Larissa,

    Larissa, Greece

  • Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA

    Pátrai, Greece

  • 2nd Department of Internal Medicine, General Hospital of Piraeus TZANEIO

    Piraeus, Greece

  • 1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki

    Thessaloniki, Greece

  • 1st Department of Internal Medicine, PAPAGEORGIOU General Hospital of Thessaloniki

    Thessaloniki, Greece

  • 2nd Department of Propedeutic Medicine, Ippokrateion University General Hospital of Thessaloniki

    Thessaloniki, Greece

  • 3rd University Department of Internal Medicine, PAPAGEORGIOU General Hospital of Thessaloniki

    Thessaloniki, Greece

  • Dipartimento di Medicina Dipartimento di Malattie Infettive, ASST Spedali civili

    Brescia, Italy

  • Unità Operativa Clinica Malattie Infettive, Ospedale Policlinico San Martino

    Genova, Italy

  • Dipartimento di Medicina Interna, Istituto Clinico Humanitas

    Milan, Italy

  • Medicina Interna, Reumatologia, Immunologia, IRCCS San Raffaele

    Milan, Italy

  • Dipartimento di Malattie Infettive e Tropicali e Microbiologia, IRCCS Ospedale Sacro Cuore Don Calabria

    Negrar, Italy

  • Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose, IRCCS Lazzaro Spallanzani

    Roma, Italy

  • Dipartimento Scienze di laboratorio e infettivologiche, Policlinico Universitario Agostino Gemelli

    Roma, Italy

  • Dipartimento di Malattie infettive e tropicali-Università dell'Insubria, ASST dei Sette Laghi

    Varese, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.